COVID-19: Siemens’ assay outperforms antibody tests from competitorsIn a Public England Health study, Siemens Healthineers’ COV2T antibody test was the only assay found to meet both sensitivity and specificity requirements of the MHRA. more ➔
AMR: Big Pharma sets up US$1bn FundAfter leaving the field of antimicrobials 20 years ago because other areas offered better returns, 23 pharma companies and the Novo Foundation have launched a US$1bn fund to fight antimicrobial resistance … more ➔
VarmX bags €32m in Series B roundLeiden-based coagulant developer VarmX NV has closed a €32m Series B financing to push clinical development of VMX-C001, a venom-based modified recombinant Factor X. more ➔
APEIRON Biologics licences MaxCyte’s electroporation platformViennese APEIRON Biologics and MaxCyte Inc have entered into licensing agreement covering the use of Maxcyte’s electroporation platform for APN401 development. more ➔
Immatics launches US$250m Nasdaq-IPOAfter closing the business merging with blank check company Arya Sciences Acquisition Corp, Immatics Inc has been listed on Nasdaq. more ➔
New insulin formulation allows faster blood sugar managementA new insulin formulation allows patients with diabetes to more quickly manage their blood sugar levels during mealtimes. more ➔
COVID-19: Lopinavir-ritonavir failedData from the UK’s RECOVERY trial demonstrate there was no clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients. more ➔
EC pledges €4.9bn to grant access to medicinesUnder the Coronavirus Global Response Framework, the European Commission is allocating further €4.9bn to assure access to COVID-19 countermeasures for poor countries. more ➔
BioGeneration Ventures closes BGV IV Fund at €105mBioGeneration Ventures has closed its fourth VC fund for European start-ups (BGV IV) at €105m. more ➔
LSP leads €11m Series A round in OneProjectOneProjects Ltd, an Irish-German cardiac imaging specialist, has closed an €11m Series A financing led by Amsterdam-headquartered life sciences investor LSP. more ➔
